Scott Leftwich serves as Executive at Calidi Biotherapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Scott Leftwich has executed 4 insider transactions totaling $250.0K, demonstrating a bullish approach to their equity position. Their most recent transaction on Aug 21, 2025 involved purchasing 125,000 shares valued at $250.0K.
Scott Leftwich currently holds 130,650 shares of Calidi Biotherapeutics, Inc. (CLDI), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Scott Leftwich has been a net buyer of CLDI stock. They have purchased $250.0K and sold $0 worth of shares.
Scott Leftwich's most recent insider trade was on Aug 21, 2025, when they purchased 125,000 shares at $2.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Mar 29, 2024 | CLDI | $0 | Award | 23,783 | $N/A | Discretionary |
| Dec 21, 2023 | CLDI | $16.1K | Award | 8,958 | $1.80 | Discretionary |